BMY241129C30000
- 0.00
- 0.000.00%
Bristol-Myers Squibb Newsroom
Optimistic Buy Rating for Bristol-Myers Squibb Driven by Promising Cobenfy Projections and Competitive Advantages
Bristol-Myers Squibb (NYSE:BMY) Increases 4.7% This Week, Taking One-year Gains to 24%
Pension Doubles Its Palantir Stake and Buys Up Intel and CVS. -- Barron's
Trump Picks Surgeon Makary to Head FDA, Rep. Dave Weldon to Lead CDC
Weekly Buzz: Nvidia Falls on Near Perfect Report, but Only For a Day
Market Climbs, Bitcoin Close to $100k | Live Stock
Replimune Climbs After Updates on Lead Drug
Bitcoin Hits $99k, Thursday Market Whiplash Following Nvidia Price | Wall Street Today
Optimism Over Global Healthcare Sector Rises: Jefferies
Bitcoin Hits $98k, Nvidia Falls on Forward Guidance, Google Chrome Break-Up | Live Stock
Nvidia Forward Guidance Was Not Perfect, Market Flat | Wall Street Today
Market Falls on Retail Results, Bitcoin Swells, All Eyes on Nvidia | Live Stock
Investing in Bristol-Myers Squibb (NYSE:BMY) a Year Ago Would Have Delivered You a 24% Gain
BRISTOL-MYERS SQUIBB CANADA WINS THE 2024 PRIX GALIEN INNOVATIVE PRODUCT AWARD
Bitcoin Climbs to Fresh High, Market Shifts into Climb | Wall Street Today
Bristol-Myers Squibb Company (BMY) Jefferies London Healthcare Conference (Transcript)
Tuesday Market Falls, SMCI Flies, Big Box Retail Reports Mixed | Live Stock
Truist Financial Maintains Bristol-Myers Squibb(BMY.US) With Buy Rating
Truist Financial Reaffirms Their Buy Rating on Bristol-Myers Squibb (BMY)
Express News | Bristol Myers Squibb’s Presentations at Ash 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms